[go: up one dir, main page]

MX2022006502A - Composiciones farmaceuticas. - Google Patents

Composiciones farmaceuticas.

Info

Publication number
MX2022006502A
MX2022006502A MX2022006502A MX2022006502A MX2022006502A MX 2022006502 A MX2022006502 A MX 2022006502A MX 2022006502 A MX2022006502 A MX 2022006502A MX 2022006502 A MX2022006502 A MX 2022006502A MX 2022006502 A MX2022006502 A MX 2022006502A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
compositions
emulsifiers
medicament
self
Prior art date
Application number
MX2022006502A
Other languages
English (en)
Inventor
Peter Surman
Fergus Binnie
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of MX2022006502A publication Critical patent/MX2022006502A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas auto-emulsionantes que comprenden un ácido graso libre insaturado, al menos dos emulsionantes y al menos un ingrediente farmacéutico activo; al uso de dichas composiciones farmacéuticas como medicamento; y a procesos para la preparación de dichas composiciones.
MX2022006502A 2019-11-27 2020-11-26 Composiciones farmaceuticas. MX2022006502A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1917252.7A GB201917252D0 (en) 2019-11-27 2019-11-27 Pharmaceutic compositions
PCT/IB2020/061183 WO2021105922A1 (en) 2019-11-27 2020-11-26 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2022006502A true MX2022006502A (es) 2022-07-04

Family

ID=69137213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006502A MX2022006502A (es) 2019-11-27 2020-11-26 Composiciones farmaceuticas.

Country Status (11)

Country Link
US (1) US20230285287A1 (es)
EP (1) EP4065084A1 (es)
JP (1) JP2023504050A (es)
KR (1) KR20220106777A (es)
CN (1) CN114746081A (es)
AU (1) AU2020392193A1 (es)
BR (1) BR112022010340A2 (es)
CA (1) CA3159491A1 (es)
GB (1) GB201917252D0 (es)
MX (1) MX2022006502A (es)
WO (1) WO2021105922A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096395A1 (en) 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
EP2243493A1 (en) * 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
CN102614114B (zh) * 2012-04-26 2013-10-02 河南中医学院 一种维生素e自乳化软膏
EP2968137B1 (en) * 2013-03-15 2021-11-10 Marius Pharmaceuticals LLC Emulsion formulations
AU2014338707B2 (en) * 2013-10-23 2020-06-04 The University Of Manchester Treatment of cancer and benign proliferative disorders
US20160235749A1 (en) * 2015-02-12 2016-08-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Micro-particulated nanocapsules containing lopinavir with enhanced oral bioavailability and efficacy
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808563D0 (en) * 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808571D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
BR112022010340A2 (pt) 2022-08-16
JP2023504050A (ja) 2023-02-01
CN114746081A (zh) 2022-07-12
GB201917252D0 (en) 2020-01-08
AU2020392193A1 (en) 2022-05-26
WO2021105922A1 (en) 2021-06-03
US20230285287A1 (en) 2023-09-14
CA3159491A1 (en) 2021-06-03
KR20220106777A (ko) 2022-07-29
EP4065084A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
PH12020550341A1 (en) Niraparib formulations
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
WO2015120110A3 (en) Novel pharmaceutical formulations
WO2020083971A3 (en) New anthelmintic compounds
MX2021006969A (es) Ligante peptidico.
SG11201808019WA (en) Edaravone formulations
WO2011113855A3 (en) Pharmaceutical composition for treatment of increased intraocular pressure
MX2022006502A (es) Composiciones farmaceuticas.
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MY202765A (en) Triesters of cyclohexanetripropionic acid
JOP20210230A1 (ar) صياغات صيدلانية
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112016026660A2 (pt) ?produto extemporâneo para cuidados cosméticos e/ou dermatológicos, e, kit de preparação extemporânea de uma composição cosmética e/ou dermatológica?
EA202191683A1 (ru) Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
MY209352A (en) Pharmaceutical composition for treating aplastic anemia
WO2020013777A3 (en) Tablet formulations comprising metformin and sitagliptin
ZA201906153B (en) Pharmaceutical compositions for combination therapy
FI20155779A7 (fi) Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
PH12019500024A1 (en) Pharmaceutical compositions
WO2017025896A3 (en) Compositions and methods for treating wounds